SEOM-GEICO clinical guidelines on endometrial cancer (2021)

被引：0
作者：
María Pilar Barretina-Ginesta
María Quindós
Jesús Damián Alarcón
Carmen Esteban
Lydia Gaba
César Gómez
José Alejandro Pérez Fidalgo
Ignacio Romero
Ana Santaballa
María Jesús Rubio-Pérez
机构：
[1] Institut Català d’Oncologia (ICO),Medical Oncology Department
[2] Department of Medical Sciences,Medical Oncology Department
[3] Girona Biomedical Research Institute (IDIBGI). Department of Medical Sciences,Medical Oncology Department
[4] Medical School University of Girona (UdG),Medical Oncology Department
[5] Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC),Medical Oncology Department, Hospital Clínic of Barcelona, Therapeutics in Solid Tumors
[6] Hospital Universitari Son Espases,Department of Medical Oncology, Infanta Sofía and Henares Hospitals Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN)
[7] Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa),Medical Oncology Department
[8] Complejo Hospitalario de Toledo,Department of Medical Oncology
[9] Translational Genomic and Targeted,Medical Oncology Department
[10] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),Medical Oncology Department
[11] Infanta Sofía University Hospital,undefined
[12] Hospital Clínico Universitario of Valencia. Biomedical Research Institute INCLIVA. CIBERONC,undefined
[13] Fundación Instituto Valenciano de Oncología (IVO),undefined
[14] Hospital Universitari i Politècnic La Fe,undefined
[15] Hospital Universitario Reina Sofía. University of Córdoba,undefined
来源：
Clinical and Translational Oncology | 2022年 / 24卷
关键词：
Endometrial cancer; Guideline; Diagnosis; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209–249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
引用
收藏
页码：625 / 634
页数：9
相关论文
共 211 条
[1]  
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2001)Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Clin Infect Dis 33 139-144
[3]  
Siegel RL(2010)Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis Obstet Gynecol 116 160-167
[4]  
Laversanne M(2018)Role of imaging in the routine management of endometrial cancer Int J Gynaecol Obstet 143 109-117
[5]  
Soerjomataram I(2019)Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer J Surg Oncol 120 864-872
[6]  
Jemal A(2020)Genetic susceptibility to endometrial cancer: risk factors and clinical management Cancers (Basel) 12 2407-S74
[7]  
Dykewicz CA(2019)Endometrial cancers in BRCA1 or BRCA2 germline mutation carriers: assessment of homologous recombination DNA repair defects JCO Precis Oncol 29 3-601
[8]  
Timmermans A(2019)Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression Int J Gynecol Pathol 38 S64-521
[9]  
Opmeer BC(2011)Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity J Oncol 2011 628084-73
[10]  
Khan KS(2021)Clinical actionability of molecular targets in endometrial cancer Gynecol Oncol 160 586-35
12345678910